How Unusual Is Zoetis’s Latest Sales Growth

For questions about this article or underlying research, email [email protected].

In its latest quarter, one large maker of medicines for pets and farm animals sold 0.24% less than it did in the same quarter a year earlier. That company is Zoetis (ZTS), and the quarter to June 2026 brought its weakest sales growth in ten years. A dip that small sounds like nothing until you set it beside what Zoetis usually does. So how fast would you guess Zoetis's sales normally grow?

How Unusual Is This For Zoetis?

Across all 40 quarters of the last ten years, Zoetis's median quarter brought sales 6.8% above the same quarter a year earlier. The table below shows the June quarter of each year.

The previous low that Zoetis broke was growth of just 0.06% in the quarter to June 2020. Even that quarter still showed growth, making this a fresh break and the first quarter in ten years where Zoetis sold less than a year earlier.

One unusual number matters most when Zoetis is a large share of what you own. See how to protect a concentrated position.

What Is Behind Zoetis's Record Low Sales Growth?

The drop came from pets. Management said on the August 6, 2026 call that Companion Animal revenue fell 6% in the quarter. Key Dermatology, Zoetis's group of skin medicines, fell harder still, by 16%.

Management pointed to fewer visits to vet clinics, pet owners watching what they spend, and U.S. price cuts on Cerenia and Convenia in response to generic competition. Medicines for farm animals went the other way, with Livestock revenue up 11%, yet total sales still slipped.

Is The Latest Quarter Still Getting Worse?

A small fall in sales is not alarming on its own. The more useful question is whether Zoetis is still moving away from its own normal. Sales grew 3.0% in the quarter to December 2025 and 2.9% in the quarter to March 2026, before falling in the quarter to June.

Over the twelve months to June 2026, Zoetis's sales still grew 1.5%. That figure lags because it captures older quarters of growth, and the newest quarter already shows sales shrinking.

When The Record Is Next Tested

On the August 6 call, management cut its fiscal 2026 sales forecast to a 2% decline at the midpoint, down from 3.5% growth in its May forecast. Management added that sales through July had not yet shown the market settling.

Over the year to October 20, 2026, Zoetis stock lost 43.4%, while the S&P 500 gained 17.1%.

When Zoetis reports on or around November 5, 2026, watch sales in the quarter to September. Management's forecast implies second-half sales about 6% below a year earlier, a far bigger fall than June's 0.24%.

Is Too Much Of Your Wealth Riding On One Stock?

One number at Zoetis has reached a level not seen in years. When one position grows into a large part of your wealth, a sharp fall can hurt your whole plan, and selling to spread the money out can bring a large tax bill. Our partner advisory firm offers a free strategy review of ways to protect a concentrated position and unwind it with less tax.

Request A Free Strategy Review

Spot an error or want more like this? Tell us in 10 seconds.